David Schilansky
non-Executive Member
Biotechnology
Lysogene
France
Biography
David Schilansky is a non-Executive Member of Lysogene’s Board of Directors Mr. Schilansky, currently Deputy CEO and Chief Operating Officer of DBV Technologies (Euronext: DBV; NASDAQ: DBVT), has 20 years of leadership experience in the field of biotechnology and finance. DBV Technologies is a late clinical-stage specialty biopharmaceutical company, for which Mr. Schilansky oversees the company’s strategic implementation. He was appointed to this role in January 2015 after serving as the Chief Financial Officer from 2011. He is a member of DBV Technologies’ Executive Committee. Previously, Mr. Schilansky held various senior positions at Ipsen Pharma, including Interim Chief Financial Officer. Earlier in his career, he worked at Thomson Inc. (now Technicolor S.A.) as co-head of investor relations and at Warburg Dillon Read (now UBS) in mergers and acquisitions. Mr. Schilansky received a master’s degree from the University of Paris Dauphine and a post-graduate degree from the Imperial College London.
Research Interest
biotechnology and finance
